Mavacamten May Improve LV Hypertrophy in Obstructive Hypertrophic Cardiomyopathy
Mavacamten was found to improve left ventricular hypertrophy in patients with obstructive hypertrophic cardiomyopathy.
Mavacamten was found to improve left ventricular hypertrophy in patients with obstructive hypertrophic cardiomyopathy.
Transgender persons who present for gender-affirming hormone therapy may be at an elevated cardiovascular risk.
Higher fitness levels were found to lower and delay the risk for atrial fibrillation among African American male veterans.
Increases in food insecurity were found to be independently associated with increased cardiovascular mortality rates in nonelderly adults.
A healthy lifestyle was found to be inversely associated with all-cause mortality, regardless of polypharmacy.
Patients who are hospitalized with COVID-19 and have an elevated vs normal troponin levels were found to be at higher risk for death.
The second-generation SAPIEN XT balloon-expandable valve was found to have a higher 5-year rate of structural valve deterioration compared with surgical aortic valve replacement.
Endocan level was found to be an independent predictor of the no-reflow phenomenon during primary percutaneous coronary intervention for STEMI.
Women with type 2 diabetes, but not prediabetes, may have a greater relative risk for prevalent cardiovascular disease than men.
Retrograde coronary venous ethanol ablation may prevent the recurrence of arrhythmias in the long-term in patients with ventricular arrhythmias refractory to drugs and radiofrequency ablation.